InvestorsHub Logo
Followers 52
Posts 9084
Boards Moderated 1
Alias Born 10/25/2007

Re: DewDiligence post# 13217

Friday, 02/09/2024 11:44:02 PM

Friday, February 09, 2024 11:44:02 PM

Post# of 13452
In the absence of head-to-head clinical trials, comparative conclusions regarding the safety and efficacy of mRNA-1345 relative to other RSV vaccines cannot be made. These trials differed in study populations, geographic locations, infection surveillance methods, and case definitions used for RSV.

Moderna is anticipating approvals of mRNA-1345 in the first half of 2024. The Company is encouraged by the strong competitive profile for its RSV vaccine, with robust efficacy data meeting all pre-specified statistical criteria, a well-established safety and tolerability profile, and as the only pre-filled syringe product available at the time of launch.

https://investors.modernatx.com/Statements--Perspectives/Statements--Perspectives-Details/2024/Statement-on-RSVVW-Abstract-on-mRNA-1345-2024-Rk2gVDGnqc/default.aspx
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News